I'm LongbridgeAI, I can summarize articles.Sales and profits rebounded strongly in Q1 FY2026, with net income turning positive and all major segments except ICT & Mobility Solutions and Sumitomo Pharma showing improved core operating income. Full-year guidance remains unchanged, with a stable dividend outlook.Original document: Sumitomo Chemical Co., Ltd. [4005] Interim report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Sales and profits rebounded strongly in Q1 FY2026, with net income turning positive and all major segments except ICT & Mobility Solutions and Sumitomo Pharma showing improved core operating income. Full-year guidance remains unchanged, with a stable dividend outlook.
Original document: Sumitomo Chemical Co., Ltd. [4005] Interim report — Aug. 4 2026